Advanced search
Publication Cover
Expert Review of Vaccines Volume 23, 2024 - Issue 1
Submit an article Journal homepage
395
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Rong Tanga Institute for Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of ChinaView further author information
,
Ying Zengb Medicine and Registration, Process Development, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, People’s Republic of China;c Medicine and Registration, Process Development, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
,
Yu Zhoub Medicine and Registration, Process Development, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, People’s Republic of China;c Medicine and Registration, Process Development, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
,
Qi Liangd Institute of Vaccine Clinical Trials, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of ChinaView further author information
,
Wei Kangb Medicine and Registration, Process Development, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, People’s Republic of China;c Medicine and Registration, Process Development, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
,
Zhonghua Yangb Medicine and Registration, Process Development, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, People’s Republic of China;c Medicine and Registration, Process Development, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, People’s Republic of ChinaView further author information
,
Xiaoxiang Zhenge Epidemic Data Processing Center, Dongtai City Center for Disease Control and Prevention, Dongtai, People’s Republic of ChinaView further author information
,
Xia Zange Epidemic Data Processing Center, Dongtai City Center for Disease Control and Prevention, Dongtai, People’s Republic of ChinaView further author information
,
Hongxing Pana Institute for Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Jing Jinb Medicine and Registration, Process Development, Yantai Patronus Biotech Co. Ltd, Yantai, Shandong, People’s Republic of China;c Medicine and Registration, Process Development, Guangzhou Patronus Biotech Co. Ltd, Guangzhou, Guangdong, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Fengcai Zhua Institute for Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 498-509 | Received 04 Dec 2023, Accepted 27 Mar 2024, Published online: 02 May 2024

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.